Clinical Research Directory
Browse clinical research sites, groups, and studies.
New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
Sponsor: University Hospital, Montpellier
Summary
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Official title: New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis
Key Details
Gender
All
Age Range
18 Years - 95 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2013-03-12
Completion Date
2031-06
Last Updated
2022-01-04
Healthy Volunteers
No
Conditions
Interventions
Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Vascular calcification score
measurement of vascular calcification score by multidetection computerized tomography
Locations (7)
AIDER
Montpellier, France
CHU Montpellier, Cardiology department
Montpellier, France
CHU Montpellier, Endocrinology department
Montpellier, France
CHU Montpellier, Intensive care unit
Montpellier, France
CHU Montpellier, Internal medicine department
Montpellier, France
CHU Montpellier, Nephrology department
Montpellier, France
AIDER
Saint-Jean-de-Védas, France